At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 17 enrolled
Drug / intervention
Telomelysindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2 Study of Telomelysin (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma
In Brief
A Phase 2 clinical trial evaluating Telomelysin for Esophagogastric Adenocarcinoma. Completed, enrolled 17 participants across 3 sites.
Detailed Summary
This is a phase II study of OBP-301 with pembrolizumab in advanced gastric and gastroesophageal junction adenocarcinoma that has progressed on at least 2 lines of prior therapy for advanced disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEsophagogastric Adenocarcinoma
CountriesUnited States
CollaboratorsOncolys BioPharma Inc
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedApr 2019
Enrollment StartMay 2019
Primary CompletionJun 2023
Study CompletionJul 2023
TodayJul 2026
First PostedApr 19, 2019
Enrollment StartMay 9, 2019
Primary CompletionJun 20, 2023
Study CompletionJul 20, 2023
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 7.2 years ago
Interventions
Telomelysindrug
OBP-301, the investigational product (IP) is formulated in 20 mM Tris pH 8.0, 25 mM NaCl with 2.5% glycerin, USP by volume. OBP-301 will be injected into the target tumor lesions.